Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,143
Out of 5,090 analysts
18
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $242.00 | +2.89% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $39.20 | -56.63% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $2.60 | +438.46% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $225.85 | -2.59% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $20.29 | +97.14% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $4.01 | +2,393.77% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $242.00
Upside: +2.89%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $39.20
Upside: -56.63%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $2.60
Upside: +438.46%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $225.85
Upside: -2.59%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $20.29
Upside: +97.14%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $4.01
Upside: +2,393.77%